Michael Callaghan resigned from Vermillion’s board on June 11, the company revealed in a document filed with the US Securities and Exchange Commission last week.
Callaghan left for personal reason and “not the result of any disagreement with the company on any matter relating to the company’s operations, policies, or practices,” Vermillion said in its document. Callaghan served on the audit and compensation committees of the board.
Miraculins said this week that company co-founder Phiet Bui is stepping down from its board and as its CSO as part of the firm’s make-over.
The company is moving away from proteomics research and discovery to diagnostic assay development and commercialization [See related story, this issue]. Before becoming CSO of Miraculins, Bui was president of the company.